ProPhase Labs, Inc. (PRPH)
NASDAQ: PRPH · Real-Time Price · USD
0.1490
+0.0110 (7.97%)
At close: Dec 9, 2025, 4:00 PM EST
0.1498
+0.0008 (0.54%)
After-hours: Dec 9, 2025, 7:59 PM EST
ProPhase Labs Revenue
ProPhase Labs had revenue of $883.00K in the quarter ending September 30, 2025, a decrease of -37.64%. This brings the company's revenue in the last twelve months to $5.06M. In the year 2024, ProPhase Labs had annual revenue of $6.77M, down -80.65%.
Revenue (ttm)
$5.06M
Revenue Growth
-80.65%
P/S Ratio
1.06
Revenue / Employee
$52,656
Employees
96
Market Cap
6.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.77M | -28.21M | -80.65% |
| Dec 31, 2023 | 34.98M | -87.66M | -71.48% |
| Dec 31, 2022 | 122.65M | 43.61M | 55.17% |
| Dec 31, 2021 | 79.04M | 64.53M | 444.59% |
| Dec 31, 2020 | 14.51M | 4.64M | 46.96% |
| Dec 31, 2019 | 9.88M | -3.25M | -24.76% |
| Dec 31, 2018 | 13.13M | 3.26M | 33.03% |
| Dec 31, 2017 | 9.87M | 5.66M | 134.59% |
| Dec 31, 2016 | 4.21M | 1.69M | 67.04% |
| Dec 31, 2015 | 2.52M | -19.55M | -88.59% |
| Dec 31, 2014 | 22.07M | -2.96M | -11.83% |
| Dec 31, 2013 | 25.03M | 2.63M | 11.72% |
| Dec 31, 2012 | 22.41M | 4.95M | 28.38% |
| Dec 31, 2011 | 17.45M | 2.95M | 20.35% |
| Dec 31, 2010 | 14.50M | -5.31M | -26.82% |
| Dec 31, 2009 | 19.82M | -691.00K | -3.37% |
| Dec 31, 2008 | 20.51M | -7.73M | -27.39% |
| Dec 31, 2007 | 28.24M | 1.39M | 5.18% |
| Dec 31, 2006 | 26.85M | -26.81M | -49.96% |
| Dec 31, 2005 | 53.66M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PRPH News
- 8 days ago - ProPhase Labs, Inc. (PRPH) Discusses Milestones in Cancer Diagnostics, Genomics Expansion, and COVID Accounts Receivable Collection Transcript - Seeking Alpha
- 13 days ago - Join ProPhase Labs' Exclusive Live Investor Webinar and Q&A Session on December 1 - GlobeNewsWire
- 20 days ago - ProPhase Labs, Inc. (PRPH) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET. - GlobeNewsWire
- 21 days ago - ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19 - GlobeNewsWire
- 22 days ago - ProPhase Labs Urges Shareholders to Vote by November 23 on Proxy Proposals - GlobeNewsWire
- 5 weeks ago - ProPhase Labs Announces Publication of BE-Smart Esophageal Cancer Study in the Official Journal of the American College of Gastroenterology - GlobeNewsWire
- 6 weeks ago - ProPhase Labs Engages RedChip Companies to Lead Investor Relations Efforts - GlobeNewsWire